Request Meetings with French Companies
Profiles of attending companies are listed below. PLEASE CHECK THIS WEBSITE REGULARLY FOR AN UPDATED LIST.
The DEADLINE to submit your meeting requests is NOVEMBER 5, 2011.
THE PROCESS:
- You will receive a confirmation email for each request made
-
UBIFRANCE will begin processing all meeting requests from November 5, 2011, and will confirm mutual interest from the other party
-
A provisional schedule will be sent to you a few days before the event and a finalized schedule on the day of the event
If you have any questions about this process, please CONTACT US.
In order to improve your chances of meeting with the companies of your choice, make your meeting requests as specific, simple and direct as possible. Include information about what your company can offer and what your company is looking for.
Affilogic
Affilogic develops Nanofitins, an alternative to antibodies for detection, capture and targeting.
More ?
COMPANY :
Affilogic partners with the industry to develop adapted binders for in vitro and in vivo uses, and moves its own pipeline of compounds (early preclinical) in particular in inflammation and CNS.
TECHNOLOGY :
Nanofitins are small, robust, efficient binders selected in vitro and manufactured in e.coli. They demonstrated extremely good performance as detection tools in immunoassays, as targeting agents, and as capture binders for affinity separation.
Affilogic is conducting several R&D programmes in inflammation and CNS to use Nanofitins both as vectors to enable active transportation, and as therapeutics with a stability opening multiple delivery strategies.
OBJECTIVES :
Affilogic is looking for partners to associate Nanofitins with existing biologics to confer additional moieties, and opportunities for strategic in vitro applications.
COMPANY INFORMATION :
-
Address :Nantes - France
- Website :http://www.affilogic.com
Close
Alsace BioValley
As a French cluster dedicated to life sciences and healthcare, Alsace BioValley represents an ideal gateway to develop any bio-business on a European scale in an efficient and swift manner.
More ?
COMPANY :
Located in Alsace (France), at the heart of Europe, its environment ensures a background particularly favourable to life sciences and healthcare. Evidence is given with the on-site presence of experts of worldwide repute, multiple platforms offering scientific services, and a lively network including 400 businesses, 60 research laboratories and 20 000 live forces. Its main mission is to federate all players – companies, research laboratories, universities – involved in life sciences & healthcare. Alsace BioValley deploys its actions along 3 main lines :- increasing the competitiveness of local life sciences & healthcare companies through a series of specialised services like commercial representation of companies at international trade fairs, search for partners and / or technologies, support in getting established ...- increasing Alsace attractivity while structuring its territory : specialised real estate, platforms offering specialised scientific services, logistics, pooled services ...- reinforcing and developing its international positioning through development of inter-clusters partnerships, exploratory missions ... Alsace BioValley is also the French representative of BioValley, the trinational cluster involved in life sciences which sweeps away the boundaries of France, Germany and Switzerland – a genuine force serving a successful opening towards Europe and the world.
TECHNOLOGY :
Alsace BioValley spans 2 main domains :
- Biopharmaceuticals: from chemistry and genes towards new drugs
- Medical technologies: medical and surgical devices, imaging and robotics
OBJECTIVES :
Alsace BioValley is your ideal partner for an easy access to: Licensing opportunities; R&D collaborations and projects funding; Innovative technological platforms; Competitive CRO and CMO; Establishment of European subsidiaries. In addition to that, we are looking to develop strategic partnerships with clusters in the US in order to foster collaboration amongst our companies and counterparts
COMPANY INFORMATION :
-
Address :9 blvd Gonthier d'Andernach - 67400 ILLKIRCH - France
- Website :http://www.alsace-biovalley.com
Close
ANS Biotech
ANS Biotech is a preclinical CRO dedicated to developing disease and efficacy models focused on pain pharmacology.
More ?
COMPANY :
ANS Biotech is a preclinical Contract Research Organization dedicated to developing disease and efficacy models focused on pain pharmacology.
On a fee for service basis, ANS Biotech offers his customers a unique combination of an extensive expertise in fundamental pharmacology of pain as well as a strong background in Research & Development for new innovative analgesics.
ANS Biotech’s mission is to support drug discovery and development efforts of his clients by enhancing their capabilities in preclinical pain research (scientific advices and project management in in vivo pharmacology and proof of concept experiments, mechanism of action studies, therapeutic positioning). In this respect, ANS Biotech proposes a relevant selection of in vivo models, especially in inflammatory pain, neuropathic pain and visceral pain.
Interestingly, ANS Biotech has also access to clinical pharmacology capabilities in pain research.
TECHNOLOGY :
Acute & Tonic Pain
Phenylbenzoquinone-induced writhing
Acetic acid-induced writhing
Formalin
Hot plate
Tail-Flick
Plantar test
Paw pressure test
Inflammatory Pain
Carrageenan-induced hyperalgesia
CFA-induced hyperalgesia
Capsaicin-induced allodynia
Kaolin-induced arthritis
CFA-induced monoarthritis
MIA-induced osteoarthritis
Postoperative Pain
Incisional pain
Visceral Pain
TNBS-induced colonic inflammatory hypersensitivity
Butyrate-induced colonic non inflammatory hypersensitivity
Stress-induced hypersensitivity
Neuropathic Pain
Chronic Constriction Injury (Bennett model)
Spinal Nerve Ligation (Chung model)
Diabetic neuropathy (STZ model)
Oxaliplatin-induced peripheral sensory neuropathy
Opioid-induced hyperalgesia
Fentanyl-induced hyperalgesia
General Behavior and Acute Toxicity
Modified Irwin grid
Consulting
Project Evaluation
Project Management
Scientific and Medical Writing
OBJECTIVES :
1) to meet american biotechs and pharmaceutical companies to provide fees for services in pain pharmacology.
2) to propose a relevant selection of in vivo models, especially in inflammatory pain, neuropathic pain and visceral pain.
COMPANY INFORMATION :
-
Address :Faculté de Médecine et Pharmacologie 28 place Henri Dunant, Bat Principal BP38 Clermont-Ferrand FRANCE - 63000 Clermont-Ferrand - Auvergne
- Website :http://www.ans-biotech.com
Close
Domain Therapeutics
Domain is a biopharmaceutical company dedicated to GPCR drug discovery and development
More ?
COMPANY :
Domain is exploiting its technology platform, DTect-All(TM), to address unexploited and orphan G-Protein Coupled Receptors (GPCRs). Domain's pipeline is ranging from hit-to-lead to preclinical candidate and the company has recently partnered its mGluR4 positive allosteric modulator project at the optimized-lead stage with Merck Serono.
TECHNOLOGY :
Domain has a proprietary and Pharma-validated technology, DTect-All(TM) able to increase the success rate of high-throughput screening campaigns. In addition DTect-All(TM) is biased for the selective identification of GPCR allosteric modulators, a novel class of safer ligands. The pipeline of Domain is composed of an mGluR4 PAM project for Parkinson's disease partnered with Merck Serono (preclinical stage), an A2A selective antagonist for Parkinson's disease under exclusive discussion with a Pharma partner (optimized lead stage), a mGluR2 NAM project for Cognition - Alzheimer's disease at lead optimization stage, an mGluR3 PAM for Parkinson's disease at hit-to-lead stage. a GLP-1R PAM program for diabetes under exclusive discussion and an undisclosed orphan GPCR project for schizophrenia conducted under a private/public consortium
OBJECTIVES :
Domain is looking for companies interested in entering into collaboration on GPCR drug discovery or in externalizing a full project: from target to IND-enabling preclinical package.
COMPANY INFORMATION :
-
Address :Bld Sebastien Brand - 67400 Illkirch - Alsace
- Website :http://www.domaintherapeutics.com
Close
Eurobiomed
Competitive cluster, one of European leaders in medicine and healthcare
More ?
COMPANY :
Our aim is to federate and strengthen the network of healthcare stakeholders, provide business development support, foster collaborative projects at the national and international level. Key figures: 200 adherents: enterprises, Universities, laboratories, support actors; 95 R&D projects financed in 2011. 5 main topics:
1) Neurosciences and aging, handicap (European project Neurorescue)
2) Medical devices, diagnostics (part of European Diagnostic Clusters' Alliance)
3) Rare and orphan diseases
4) Immunology and therapeutic applications
5) Infectious, tropical and emerging diseases
TECHNOLOGY :
Neurosciences/ neurodegeneration attributed technologies (about 20 enterprises specializing in Neurosciences make part of our network). Particular focus on the treatment of Alzheimer's disease.
OBJECTIVES :
Networking
Search for people interested in French-American Biotech Symposium 2012 (new therapeutic approaches of aging)
Search for potential partners for collaborative projects,
Exchange on the R&D financing topics
Discussion of the research agenda in neurosciences
COMPANY INFORMATION :
-
Address :2 rue Henri Barbusse - 13001 Marseille - Provence-Alpes Côte d'Azur, Languedoc-Roussillon
- Website :http://www.eurobiomed.org
Close
ICDD
Delivering confidence in drug development
More ?
COMPANY :
ICDD is a science-based biotech dedicated to diagnostic biomarkers development in safety and personal medicine. We are focused on high value biomarkers at preclinical and clinical stage.
The preclinical biomarkers rely on 2 technologies, Mitosafe® and Mitostream®, based on the use of mitochondria functions or behaviours to predict toxicity with a high efficiency. Used early in the development process, ICDD’s products and services allow healthcare companies to select safer products and to reduce overall product development costs. Both technologies are already available as services, technology transfers but also partnerships with fees for success.
Compagnon diagnostics (PMDx) is the future of ICDD. Through our patented Promembrane® platform we address 2 unmet medical needs: early diagnosis of Alzheimer disease and muscle adverse events.
TECHNOLOGY :
ICDD is a science-based biotech with a strong and unique expertise in mitochondrial function and behavior applied to neurodegeneration. We identify cellulomic signatures of CNS disease such as AD and HD in human primary cells studying mitochondrial behavior. Through a process called Mitoselect, we can select drugs that reverse the disease-associated signatures. We would like to present to you this innovative process for helping you choose the best compound.
OBJECTIVES :
patnership with pharmaceutical companies developping disease modifyers drugs
COMPANY INFORMATION :
-
Address :100 route des houillères BP-2 - 13590 MEYREUIL - FRANCE
- Website :http://www.icdd-sas.com
Close
Institut du Cerveau et de la Moelle épinière ICM
ICM is a private not for profit Institute dedicated to translational research on nervous system diseases
More ?
COMPANY :
ICM is a research institute dedicated to translational research on nervous system diseases. It merges the forces of nearly 5OO researchers, engineers and clinicians and is in close partnership with CNRS, INSERM, UPMC and APHP
OBJECTIVES :
Industrial partnerships
COMPANY INFORMATION :
-
Address :Hôpital de la Pitié Salpêtrière 47 boulevard de l'Höpital - 75013 Paris - France
- Website :http://www.icm-institute.org
Close
Ipsen
Global biopharmaceutical group focused on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology and on primary care drugs
More ?
COMPANY :
Ipsen is a global biopharmaceutical group, with sales exceeding 1.1 billion euros in 2010. The Group has total worldwide staff of more than 4,400 employees, of which more than 900 contribute to the discovery and development of innovative drugs for patient care. Ipsen’s development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology and on primary care drugs. This strategy is supported by an active policy of partnerships. Ipsen’s research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales.
OBJECTIVES :
Discuss potential partenerships in the field of Neurology
COMPANY INFORMATION :
-
Address :27 Maple street - 01757 Milford - MA
- Website :http://www.ipsen.com/en
Close
METABOLYS
Metabolys acts as a CRO to predict the safety and efficacy of drug candidates through cellular metabolomics
More ?
COMPANY :
Metabolys predicts the safety and efficacy of drug candidates by assessing early during the development process their adverse and beneficial interactions with cellular pathways in any human or animal cell type in vitro.
TECHNOLOGY :
For this, Metabolys uses cellular metabolomics which comlbines the incubation of metabolically differentiated cells (brain, liver, kidney, etc...) with (i) the measurement of the consumption of physiological 13C-labeled substrates (glucose, glutamate, glutamine, etc...) and product formation by both enzymatic and carbon 13 NMR techniques and (ii) original mathematical models of metabolic pathways. This approach provides a panoramic view not only of the cellular metabolic pathways (including the Krebs cycle) but also of the adverse and beneficial effects of milligram amounts of test compounds. This significantly reduces the risk, cost and time of drug development.
OBJECTIVES :
-show how our approach reduces the risk, cost and time of the drug development process
- establish collaborations with pharma or biotech companies interested in this approach
COMPANY INFORMATION :
-
Address :Laennec Faculty of Medicine, 12 rue G. Paradin, - 69372 Lyon Cedex 08 - France
- Website :http://www.metabolys.com
Close
Neurorescue
NeuroRescue project aims at stimulating the cooperation, the exchange and the dissemination of best practises at the European level.
More ?
COMPANY :
Implemented under the Seventh Framework Program (FP7) the project NeuroRescue, started on December 1st, 2010, gathers six partners from four countries.
With a strong focus on neurodegenerative and ageing related diseases like Alzheimer, Parkinson or Dementia the NeuroRescue project aims at stimulating the cooperation, the exchange and the dissemination of best practises at the European level.
OBJECTIVES :
Networking,share experiences
COMPANY INFORMATION :
-
Address :Marseille - France
- Website :http://www.neurorescue.eu
Close
PhenoPro
Advanced mouse phenotyping, pharmacological studies and translational research covering various therapeutic areas to improve your drug discovery pipeline
More ?
COMPANY :
PhenoPro is a spinout of the Mouse Clinical Institute (MCI)*, one of the prime research institutes in mouse genetic engineering and mouse model phenotyping, with a successful track record of partnerships with Pharma and Biotech companies.
PhenoPro ambitions to be a worldwide leader in servicing Pharma & biotech companies with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug discovery & development productivity and patient access to safer and more efficacious drugs.
PhenoPro benefits from interactive technology platforms, combining specialized scientific expertise and know how, and offering a comprehensive array of state of the art mouse phenotyping test panels, addressing most of organs and covering the following therapeutic areas:
- metabolic (diabetes, obesity, etc…)
- cardiovascular (hypertension, congestive heart failure, arrhythmias, etc…)
- pulmonary (asthma, etc..)
- central and peripheral nervous system (anxiety, depression, epilepsy, cognitive impairment, etc..)
- immunology (allergy, inflammation, etc..)
- hematology
- endocrinology
- sensory systems (retinopathy, etc..)
PhenoPro provides customers with PhenoPro Packs which encompass:
- experimental setting: phenotyping protocols (including mouse strains, disease model, diet, pharmacological exposure) in a range of functions
o standardized (predefined protocols in a wide range of functions)
o customized (protocols and range of assessed functions defined jointly with the customer)
- project planning & management
- project reporting (via CD ROM, e-reporting, database access):
o raw data
o data analysis: statistical, contextual (i.e. based upon multidisciplinary literature review)
- recommendations
TECHNOLOGY :
PhenoPro provides standardized, comprehensive or advanced, functional characterization of mouse models to better understand the function of genes, basic mechanisms of biology, pathophysiology of diseases, to identify and validate new drug targets and to perform risk assessment.
More than 250 phenotyping assays have been validated to cover a wide range of functions:
- The Neurobiology and Behavior service has developed a test battery adapted to the mouse. This includes analysis of sensory responses, motor abilities, cognitive functions and behaviors related to symptoms of neuropsychiatric disorders such as anxiety, depression and schizophrenia. Tests may be utilized as a package for phenotyping genetically modified mice or to screen for potential therapeutics. Alternatively, individual tests may be used as required.
- The Cardiovascular service is designed to detect the main cardiac phenotypes: congenital cardiac disease, ventricular dysfunctions, cardiac hypertrophy and dilatation, trouble of conduction, arrhythmias, hypertension and hypotension. We also propose several pathological models to reveal phenotypes in genetically mouse models mice or to test compounds.
- Different tests enable also to explore mechanisms involved in lung inflammatory diseases such as airway hyperreactivity and bronchial inflammation in order to phenotype genetically engineered mice and / or to screen in vivo potential therapeutic drugs.
- The Metabolic Exploration service performs specific, on-demand experiments as well as comprehensive metabolic analysis with primary and secondary phenotypic screens to evaluate in vivo the energy balance in mouse. These screens are performed under either basal condition or energy challenges using standardized techniques for the detection of phenotype in energy metabolism, glucose homeostasis, intestinal function, bone metabolism and renal function. The platform provides users with techniques and scientific support for the design of experimental protocols as well as for the development of new techniques for the investigation of metabolism. The Metabolic Exploration service has large experience in phenotyping mouse model for diabetes, obesity and atherosclerosis.
- The laboratory of clinical chemistry performs a large panel of tests in blood, urine and tissue samples. The measurement of various blood metabolites, ions and enzymes gives a screening of the major metabolic function such as water and sodium distribution, kidney, liver and gastrointestinal tract. Most of the endocrine functions can be evaluated through the measurement of several circulating hormones. Blood hematology, immunology and coagulation parameters are also performed.
- The Histopathology and Embryology facility provides a comprehensive histopathological analysis of mutant or treated mice. Various histological procedures are applied to detect and analyze systematically organ defects and tissue alterations in mice at precise stages of their developmental history, and in adult and ageing mice. The facility also has the capacity to perform analysis of cell proliferation and apoptosis and immunohistochemical assays using commercialy available antibodies.
OBJECTIVES :
The objectives for this event is to find new partnerships with pharma and biotech companies, to help to accelerate their drug discovery process, avoid late stage pullbacks and limit the research costs
COMPANY INFORMATION :
-
Address :1 rue Laurent Fries - 67400 Illkirch - France
- Website :http://www.phenopro.com
Close
Rhenovia Pharma
Rhenovia Pharma: Pioneer of Biosimulation in Neuroscience for Optimization of Drug Discovery and Development serving Pharma and Biotech Industry
More ?
COMPANY :
RHENOVIA PHARMA is a world leading biotechnology company in biosimulation applied to drug discovery and development (DD&D) for the nervous system (NS). Created by seasoned professionals of the top-tier global pharmaceutical industry, world experts in neurobiology, especially cognition and neuropharmacology, and pioneers in computational neuroscience, Rhenovia is an independent international company headquartered in France with branches in the US, Germany and Switzerland and a team of 20 collaborators.
Fulfilling urgent unmet medical needs
Rhenovia is elaborating innovative technologies aiming at identifying better treatments for diseases of the central (brain, eye, spinal cord) and peripheral (muscle) nervous system with a first focus on Alzheimer’s disease followed by other brain diseases such as depression, schizophrenia, bipolar disorder, epilepsy, stroke, Parkinson’s disease as well as rare/orphan diseases like Huntington or Niemann Pick disease. Further developments target pain, addiction and muscular dystrophies. Rhenovia’s basic conceptual approach is to exploit the two major hallmarks of NS diseases: the complexity of biological systems by building a computer modeling and simulation platform, and the multifactorial feature of NS by searching for multi-target synergistic drug combinations. Basically, the objective is to address the major causes of failures including testing drugs under pathological conditions, anticipating losses of efficacy due to bell-shaped curves or risks of side effects such as cognitive impairment, pro-convulsive effects and syndromes linked to disruption of the Glu/GABA homeostasis
Changing the business environment
The objective is to revolutionize the DD&D by preceding experimentation by simulation and thereby improving success rate and efficacy, and reducing development cost and time to market. In addition to the first focus on exploitation of its modeling and simulation platform, Rhenovia also develops complementary and supportive technologies directed at other levels of the DD&D value chain. Among them, Rhenovia has reached the stage of a prototype of a unique device for transdermal drug delivery containing nine innovations for the release of drugs controlled in time and concentration, which will allow optimal administration of drug combinations. The goal is to move towards individualized medicine, to increase compliance and to decrease risks of toxicity especially in elderly people.
Creating momentum via punctual service offerings, longer term partnerships and strategic option alliances
Rhenovia provides several high value added service – partnership programs to the pharma and biotech industry for optimization of their DD&D at any stage of drug development, from the very early research and discovery phase up to strengthening the life cycle of marketed drugs reaching patent expiration. With a ‘High Throughput Synergistic Drug Combination Program’, Rhenovia offers to leverage on the existing drugs of the partners by searching for synergistic combinations that address the multifactorial feature of diseases by improving efficacy vs side effect, creating differentiation from competitors and providing solutions to extend the life cycle of marketed drugs. Rhenovia offers its new tools ‘Quantitative Compounds Profiling’, ‘Numerical Target Identification’, ‘Alternative In Silico Flowchart’, and ‘Analyses of Safety/Toxicity Alerts’ aiming at preceding and complementing the animal experimentation and increasing the success rate of in and out-licensing.
TECHNOLOGY :
RHENOVIA’S MODELING & SIMULATION PLATFORM (RHENOMS™ PFG-1)
Rhenovia possesses the most elaborated biosimulation platform directly applicable to Drug Discovery & Development (DD&D). RHENOMS™ models the excitatory and inhibitory neuronal transmission with the pre-, intra- and postsynaptic electrical, biophysical and biochemical events involving the major signalling cascades downstream to GPCRs, ligand- and voltage-gated ion channels and its modulation by the cholinergic system. The first proprietary platform simulates cognitive deficit (long-term potentiation) and other pathologies in the brain, eye, spinal cord and muscular junction associated with the GLU/GABA homeostasis and Ca2+ and acetylcholine deregulation. Further developments expand the application fields to most neurological and psychiatric indications.
Rhenovia’s modeling and simulation technology rests on the following basics:
- Reproduce bench experiments on the computer
- Mathematic modeling and translation of the biochemical reactions involved in neuronal transmission at the level of the synapses, the neurons, the neuronal networks and circuits
- Computer prediction of drug properties to identify new applications
- Experimental confirmation validation
RHENOMS™ PFG-1 is operational and validated.
Rhenovia’s first platform is operational for the testing of drug action at any molecular site of the glutamate/GABA synapse. All the components of the synapse are represented in their dynamic and not static form with the various phase transitions linking the GPCRs with their downstream cascades, the ion channels with their movement towards opening, closing and desensitization states.
The validation has been obtained either by reproducing in the simulation experimental data, or by being able to confirm in the experiment, predictions generated by the simulation. The most relevant validation data have been obtained in the course of a partnership with a big pharma. Rhenovia identified synergistic combinations among drug candidates in clinical development that have been validated experimentally by the partner.
Reproduce bench experiments and assess multiple variables under physiological and pathological conditions
RHENOMS™ PFG-1 allows:
? to perform a variety of bench experiments such as
• Intra/extracellular electrophysiology
• Patch clamp
• Calcium Imaging
• Microdialysis/neurotransmitter release
• Enzymatic activity (i.e. AChE)
• Receptor –ion channel binding
• cAMP/cGMP formation
• IP3, 2AG synthesis
• Neuronal/glial uptake
? To assess multiple variables such as
• Membrane potential
• Selective ionic currents (Na+, K+, Ca2+)
• LTP, LTD
• Ligand & voltage gated ion channel function (transition between states, currents, open probability; AMPAR, NMDAR, nAChR, GABAAR)
• Gq, Gi, Gs coupled receptor functions (second messengers i.e. IP3, DAG, cAMP; GPCRs i.e. mGluR1/5, mGluR2/3, H3, CB1, A1, mACh, 5-HT6, GABAB)
• Pre and postsynaptic Ca2+ transients
• Transport rate (glycine, glutamate, Na/Ca exchanger)
• Enzymatic activity and degradation (AChE, BuChE,CamKII, PKA, PKC, PLC, Ca-ATPase, calmodulin, calcineurin)
OTHER PRODUCTS FOR OUT-LICENSING
RHEDAR: is a CNS drug candidate for repositioning as orphan drug, formerly in Phase 2, offered for out-licensing
ALTHERAS: is an innovative transdermal device for rate controlled release of drugs or drug combination particularly suited for personalized medicinal therapies
IFT: Isoelectric Filtration Technology is a innovative, highly sensitive, low cost, industrially scalable technique particularly suited for the purifications of peptides and proteins such as antibodies, siRNA, isoforms of enzymes and bioengineered drugs.
OBJECTIVES :
We expect to meet pharma and biotech companies to offer several collaborative programs and to perform an opportunity assessment for the highest added value of the partners:
? RHEDDOS™-1 (RHEnovia Drug Development Optimization Service):
Is a regular fee-for-service offering by simulation–based investigations to validate new targets and leads, enhance development candidates or guide go/no go decision making.
? RHEDDOS™-2 :
Is a milestone-driven fast track partnership with a very high added value for full discovery programs
? Option alliances:
Is an in – out option deal, milestone driven for the development of customized biosimulation platforms under exclusive license.
COMPANY INFORMATION :
-
Address :20C rue de Chemnitz - 68200 Mulhouse - Alsace
- Website :http://www.rhenovia.com
Close
SynapCell SAS
SynapCell provides translational solutions to evaluate the therapeutic potential of CNS drug candidates in epilepsy, neuroprotection and synaptic plasticity.
More ?
COMPANY :
SynapCell is a preclinical Contract Research Organization realizing research projects for biotech and pharmaceutical companies involved in the development and promotion of drug candidates in the field of CNS pathologies. Our aim is to translate preclinical results into predictive clinical validation in epilepsy, neuroprotection and synaptic plasticity.
To our mind, it is essential to identify the best drug candidates as early as the preclinical step in order to improve clinical development efficiency. We are deeply convinced that this improvement relies on the development of both translational models and cutting-edge processes.
Our missions are to:
- qualify the therapeutic potential of your lead compounds through our highly predictive solutions;
- provide a great added value to your drug candidates with a precise targeting of their future indication;
- optimize your CNS drug development by increasing the probability of clinical success whilst saving valuable time and money.
TECHNOLOGY :
SynapCell provides customized solutions which cover the entire range of customers needs, from early steps to the final answer.
In vivo:
We assess the anti-epileptic, anti-epileptogenic or pro-epileptic effects of your drug candidates through :
- predictive animal models of epilepsy
- protocols mimicking clinical trials (e.g., cross-over, add-on, chronic treatment)
- quantitative results using EEG.
In vitro:
We define the activity profile of your drug candidates on neuronal network through :
- integrated models on acute / organotypic brain slices
- various experimental conditions (e.g., physiological, excitotoxic, epileptic)
- multisite recording using MEA.
OBJECTIVES :
Scientific and business partnerships
COMPANY INFORMATION :
-
Address :Pépinière Biopolis 5 avenue du Grand Sablon - 38700 La Tronche - France
- Website :http://www.synapcell.com
Close
Ubifrance
Ubifrance is the French agency for international business development. Our mission is to assist French exporters in building international partnerships and exploring business opportunities.
More ?
COMPANY :
Based in New York, San Francisco and Chicago, the US Biotech Team works with more than 300 French and 500 US biotech companies each year. Our services include targeted market research, international business development assistance, identifying potential partners and organizing biotech conferences. UBIFRANCE welcomes the opportunity to help US companies and organizations in building connections with the French biotech industry. These service are free.
OBJECTIVES :
We are interested in meeting both French and American companies in the biotech industry that are seeking international licensing, partnership, or collaboration opportunities.
COMPANY INFORMATION :
-
Address :88 Kearny Street, Suite 700 - 94108 San Francisco - CA
- Website :http://www.Ubifrance.com
Close